tiprankstipranks
Merck, AstraZeneca: LYNPARZA/abiraterone and prednisone combo approved in EU
The Fly

Merck, AstraZeneca: LYNPARZA/abiraterone and prednisone combo approved in EU

AstraZeneca (AZN) and Merck (MRK), known as MSD outside of the United States and Canada, announced that LYNPARZA has been approved in the European Union in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated. This approval by the European Commission follows the positive recommendation from the Committee for Medicinal Products for Human Use received in November this year and was based on the Phase 3 PROpel trial, results of which were published in NEJM Evidence in June 2022.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MRK:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles